MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-11-2026
Organovo Holdings EBITDA 2011-2026 | ONVO
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Organovo Holdings
| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -12.4 M | -14.8 M | -17.4 M | -16.8 M | -20.6 M | -26.3 M | -34 M | -37.4 M | -37.8 M | -29.8 M | -20.3 M | -3.95 M | -9.12 M | -118 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -118 K | -37.8 M | -20.1 M |
Quarterly EBITDA Organovo Holdings
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -2.85 M | - | - | - | -3.32 M | - | - | - | -4.13 M | - | -3.36 M | -3.12 M | -3.19 M | - | -3.5 M | -9.47 M | -6.01 M | - | -2.49 M | -2.47 M | -8.94 M | -2.78 M | -5.23 M | -4.1 M | -6.45 M | -6.32 M | -6.53 M | -5.7 M | -5.44 M | - | -7.91 M | -9.58 M | -9.87 M | - | -9.63 M | -27.1 M | -17.8 M | - | -10.5 M | -29.7 M | -19.4 M | - | -6.96 M | -22 M | -15.2 M | - | -4.63 M | -13.7 M | -9.15 M | -3.94 M | -2.92 M | -7.81 M | -4.97 M | -1.31 M | - | -573 K | -441 K | -476 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -441 K | -29.7 M | -7.69 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Diagnostics research industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
1.67 B | $ 115.35 | -2.33 % | $ 35.1 B |  USA |
 |
Anixa Biosciences
ANIX
|
-11.7 M | $ 2.81 | -2.7 % | $ 91.2 K | USA |
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 12.28 | -2.69 % | $ 99.4 M |  Israel |
|
Akumin
AKU
|
70.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Check-Cap Ltd.
CHEK
|
-25.8 M | - | - | $ 9.42 M | Israel |
 |
Aspira Women's Health
AWH
|
-32.5 M | - | -6.19 % | $ 10.5 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
-749 M | $ 22.48 | -1.58 % | $ 234 M |  China |
 |
Bioventus
BVS
|
101 M | $ 8.45 | -7.14 % | $ 563 M | USA |
 |
Celcuity
CELC
|
-113 M | $ 114.85 | -0.34 % | $ 4.53 B | USA |
 |
Castle Biosciences
CSTL
|
24.7 M | $ 27.23 | -2.44 % | $ 756 M | USA |
 |
Charles River Laboratories International
CRL
|
428 M | $ 175.23 | -3.37 % | $ 8.69 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-3.26 M | - | - | $ 562 M |  Britain |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Co-Diagnostics
CODX
|
-41.5 M | - | - | $ 79.8 M | USA |
 |
Fulgent Genetics
FLGT
|
-49 M | $ 14.59 | 2.41 % | $ 441 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-12.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
652 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-35.1 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-6 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
416 M | - | - | $ 10.7 B | USA |
|
Biodesix
BDSX
|
-28.7 M | $ 18.61 | 17.37 % | $ 2.41 B | USA |
 |
Biocept
BIOC
|
-30.3 M | - | -13.05 % | $ 7.29 M | USA |
 |
Illumina
ILMN
|
-479 M | $ 124.76 | -2.71 % | $ 19.8 B | USA |
 |
IQVIA Holdings
IQV
|
3.33 B | $ 175.33 | -1.8 % | $ 30.1 B | USA |
 |
BioNano Genomics
BNGO
|
-90 M | $ 1.11 | -1.36 % | $ 1.41 M | USA |
 |
Heska Corporation
HSKA
|
-6.33 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.2 M | - | -20.0 % | $ 1.06 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
2.13 B | $ 199.8 | -2.07 % | $ 22.2 B | USA |
 |
Danaher Corporation
DHR
|
5.44 B | $ 195.75 | -2.99 % | $ 140 B | USA |
 |
IDEXX Laboratories
IDXX
|
1.51 B | $ 607.19 | -1.9 % | $ 48.8 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-81.4 M | $ 103.5 | 0.17 % | $ 19.5 B | USA |
 |
DarioHealth Corp.
DRIO
|
-55.7 M | $ 9.69 | -3.0 % | $ 275 M | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
2.07 B | $ 269.52 | -2.34 % | $ 22.4 B | USA |
 |
DexCom
DXCM
|
1.16 B | $ 68.5 | -3.1 % | $ 26.7 B | USA |
 |
QIAGEN N.V.
QGEN
|
301 M | - | - | $ 10.6 B |  Niderland |
 |
ICON Public Limited Company
ICLR
|
1.59 B | $ 107.08 | -3.19 % | $ 8.83 B |  Irlanda |
 |
Lantheus Holdings
LNTH
|
381 M | $ 72.86 | -4.53 % | $ 4.92 B | USA |
 |
CareDx, Inc
CDNA
|
-15.8 M | $ 17.91 | -4.48 % | $ 954 M | USA |
 |
Chembio Diagnostics
CEMI
|
-21.1 M | - | 0.22 % | $ 16.8 M | USA |
 |
Mettler-Toledo International
MTD
|
51.1 M | $ 1 215.85 | -3.66 % | $ 25.1 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
-334 M | $ 5.15 | 0.29 % | $ 477 M | USA |
 |
NeoGenomics
NEO
|
-79.8 M | $ 8.92 | -2.3 % | $ 1.14 B | USA |
 |
National Research Corporation
NRC
|
30.2 M | $ 14.48 | 3.13 % | $ 324 M | USA |
 |
Guardant Health
GH
|
-398 M | $ 91.56 | -1.1 % | $ 11.5 B | USA |
 |
Natera
NTRA
|
-524 M | $ 196.94 | -0.1 % | $ 19.4 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.5 M | - | -34.28 % | $ 263 K | Israel |
 |
OPKO Health
OPK
|
-53.9 M | $ 1.18 | 0.43 % | $ 819 M | USA |
 |
Enzo Biochem
ENZ
|
-11.1 M | - | -8.98 % | $ 14.8 K | USA |